This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back or does not respond to treatment. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participa
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
Decitabine is a demethylating agent and vorinostat is a HDAC inhibitor. The use of demethylating agents and HDAC inhibitors in combinatio
To learn more about available leukemia clinical trials, contact us at email@example.com or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2018 Cincinnati Children's Hospital Medical Center. All rights reserved.